Home / Health / New Therapy Offers Hope for Severe Inflammatory Bowel Disease
New Therapy Offers Hope for Severe Inflammatory Bowel Disease
5 May
Summary
- New drug combination therapy shows promise for IBD patients.
- Trials tested drugs on Crohn's disease and ulcerative colitis patients.
- Combination therapy achieved higher remission rates in resistant patients.
A new experimental therapy combining golimumab and guselkumab is demonstrating considerable success in treating patients with severe inflammatory bowel disease (IBD) who have exhausted conventional options. Results from two Phase 2b randomized controlled trials, presented at Digestive Disease Week in Chicago, indicate that this combination approach can significantly improve clinical remission rates.
One trial focused on 693 patients with Crohn's disease, while the other involved 572 patients with ulcerative colitis. Both trials enrolled individuals whose conditions were moderate-to-severe and had not responded to at least one prior drug therapy. For the most treatment-resistant patients in the Crohn's trial, 49.2% achieved clinical remission after 48 weeks with the combination therapy, compared to much lower rates with single drugs.
This combined therapy targets different proteins that drive inflammation, offering a dual mechanism of action. Experts suggest this could be a breakthrough for the estimated 10-20% of IBD patients who face multiple treatment failures, a group often left with surgery as the last resort. Larger Phase 3 trials are anticipated to begin later in 2026 to further validate these encouraging findings.
